Housing New Mexico launches program aiming to increase affordable housing
The board of directors for Housing New Mexico approved the Notice of Funding Availability for $656,000 at a February meeting. One major goal is to create higher-quality home options for tenants using housing-based vouchers, such as Section 8 and Linkages, as well as municipal and county rental assistance.
The program offers forgivable loans of up to $25,000 per unit to landlords either leasing or agreeing to lease their properties to housing voucher holders. Housing New Mexico says these loans will help with necessary improvements to the rental units.
Albuquerque mayor files complaint against city council over AFR staffing ordinance
'Whether it's single-family homes or rental properties, New Mexico is in great need of affordable housing for its residents,' Housing New Mexico Executive Director and CEO Isidoro Hernandez said in a news release on Tuesday. 'This program is a win-win in that it will help landlords with funding to bring rentals up to standards and will provide more opportunities for affordable housing in the state.'
Housing partners are currently being invited to submit applications to become service providers. Those service providers will work with public housing authorities and other governmental agencies offering vouchers to submit house rehabilitation projects for private landlords. Eligible applicants should have experience and knowledge of housing assistance and property rehabilitation, including:
Non-profit organizations
For-profit organizations
Public housing authorities
Regional housing authorities
Tribal governments
Tribal housing agencies
Applications are welcome to join a webinar on Wednesday, April 2 at 11 a.m. More information can be found online.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript, titled 'A Phase 3 Trial of Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis' Following the online publication in NEJM, the manuscript will be available on the Congresses & Publications page of the Company's corporate website. 'IMPALA-2, the largest and longest Phase 3 clinical trial conducted in patients with autoimmune PAP, demonstrated that 48 weeks of once daily administration of inhaled molgramostim addresses the underlying pathophysiology of this chronic rare lung disease,' said Bruce Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine and Lead Clinical Investigator of the IMPALA-2 trial. 'Treatment with molgramostim improved the cardinal manifestations of autoimmune PAP, namely it reduced pulmonary surfactant burden and improved pulmonary gas transfer, respiratory health-related quality of life, and patient functionality. Additionally, molgramostim was well tolerated with no notable safety concerns.' IMPALA-2 achieved statistical significance on its primary endpoint, change from baseline in the hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLco%) at Week 24. Molgramostim significantly improved pulmonary gas transfer as measured by DLco% at Week 24 compared with placebo (9.8% vs. 3.8%; estimated treatment difference, 6.0%; P<0.001 by comparison of least-squares means [LSMs]). The beneficial effect of molgramostim on pulmonary gas transfer was maintained to Week 48 as shown by the difference in LSM change from baseline in DLco% at Week 48 between molgramostim and placebo groups (11.6% vs. 4.7%; estimated treatment difference, 6.9%; P<0.001). The mean improvements in DLco% from baseline for molgramostim (9.8% at Week 24 and 11.6% at Week 48) are similar to the minimal clinically meaningful difference (MCID) in DLco% of 10% reported for pulmonary fibrosis. 1 Molgramostim improved respiratory health-related quality of life as measured by the St. George's Respiratory Questionnaire (SGRQ) Total and Activity scores. The magnitude of LSM reduction from baseline in SGRQ Total score was significantly greater in the molgramostim group than placebo at Week 24 (-11.5 points vs. -4.9 points, estimated difference, -6.6 points; P=0.007) and remained numerically greater at Week 48 (-10.7 points vs. -5.9 points, estimated difference, -4.9 points [95% confidence interval, -10.8, 1.0]). The LSM change from baseline in SGRQ Activity score was greater for molgramostim compared with placebo at Week 24 (-13.0 points vs. -5.2 points, estimated difference, -7.8 points [95% confidence interval, -14.1, -1.5]) and at Week 48 (-13.4 vs. -7.4 points, estimated difference, -6.0 points [95% confidence interval, -13.6, 1.6]). Molgramostim improved patient function as measured by exercise capacity (expressed as peak metabolic equivalents [METs]). A MET is a unit of resting oxygen uptake which measures energy expenditure. The LSM change from baseline in peak-METs was greater at Week 48 for molgramostim than placebo (1.1 vs. 0.6; estimated treatment difference, 0.6; [95% confidence interval, 0.1, 1.0]). Peak-METs is a clinically useful unit of measure reflecting exercise capacity, prognosis, and mortality in cardiovascular disease for which a 0.5-MET increase comprises a clinically useful measure of rehabilitation. 2 Using the treadmill test in IMPALA-2, the LSM change in peak-METs from baseline to Week 48 was 1.1 in molgramostim-treated patients and the between-group difference observed at Week 48 was 0.6 peak-METs. Molgramostim reduced surfactant burden as measured by ground glass opacity (GGO) score, an exploratory endpoint in IMPALA-2; GGO scores were determined by two blinded radiologists from a chest CT scan, with scores ranging from 0 to 15 (higher scores are worse). The mean reduction from baseline in GGO score was greater in the molgramostim group than the placebo group at Week 24 (-2.1 vs -1.1). Further, the number of patients who received ≥1 whole lung lavage as rescue therapy during the double-blind intervention period was lower with molgramostim than placebo (6 [7%] vs. 11 [13%]). In IMPALA-2, molgramostim was well tolerated. Most treatment-emergent adverse events (AEs) were mild or moderate, and few led to discontinuation, with 98% of patients in the molgramostim group and 96% of patients in the placebo group completing the 48-week double-blind period on treatment. About IMPALA-2 IMPALA-2 was a global, pivotal, Phase 3, 48-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the efficacy and safety of molgramostim 300 mcg self-administered once daily by inhalation with matching placebo in patients with autoimmune PAP. The trial was conducted at 43 clinical trial sites across 16 countries, including the U.S., Canada, Japan, South Korea, Australia, and countries in Europe, including Turkey. The primary efficacy assessment was hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLco%), a gas transfer measure, and the primary endpoint was change from baseline to Week 24 in percent predicted DLco%, with a secondary endpoint of change from baseline to Week 48 in percent predicted DLco%. Three additional secondary efficacy variables evaluated clinical measures of patient benefit: St. George's Respiratory Questionnaire (SGRQ) Total score, SGRQ Activity score, and exercise capacity using a treadmill test, with each endpoint measured at Weeks 24 and 48. The primary time point for efficacy assessments was at Week 24; however, efficacy was assessed through Week 48 to evaluate durability of effect. Safety was assessed through Week 48. All patients who completed the 48-week double-blind treatment period continued into a 96-week open-label period during which molgramostim 300 mcg is administered once daily. Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas transfer, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at and LinkedIn. 1 Raghu G, et al. Am J Respir Crit Care Med 2022;205:e18-e47. 2 Ross R, et al. Circulation 2016;134:e653-e99; Grace SL, et al. Can J Cardiol 2014;30:945-8; Kehler DS, et al. J Cardiopulm Rehabil Prev 2017;37:250-6.
The Verge
8 hours ago
- The Verge
Amazon now sells used Hertz rental cars
Hertz has announced that it will start selling used cars from its rental business on Amazon Autos. The company's pre-owned vehicles are now available in Dallas, Houston, Los Angeles, and Seattle, according to a new page on Hertz's website, with 'more locations coming soon.' The Verge was unable to find any live Hertz vehicle listings at the time of writing. CNBC reports that customers living within 75 miles of the four launch cities can start browsing on Amazon Autos 'as soon as Wednesday' and that Hertz is planning to expand its operation to 45 locations across the US, bringing availability more in line with the wider list of Amazon Autos locations. 'Now you can conveniently shop our maintained-from-day-one vehicles on the online marketplace of - well - just about everything else,' Hertz says on its website. 'Just shop at Amazon Autos and pick up at your local Hertz Car Sales location within 3 days.' Amazon launched its Autos business in December last year, initially limited to selling new and 'certified pre-owned' Hyundai vehicles via a partnership with the Korean automaker's dealers in several states. Previously, customers could browse car showrooms and compare prices on Amazon but not actually buy a car. That changed last year when several Hyundai dealers started to list models for sale on the site. Hertz is the first rental fleet partnership for Amazon Autos, and will offer used vehicles from a wider variety of brands, including Ford, Toyota, Chevrolet, and Nissan. Posts from this author will be added to your daily email digest and your homepage feed. See All by Jess Weatherbed Posts from this topic will be added to your daily email digest and your homepage feed. See All Amazon Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Tech Posts from this topic will be added to your daily email digest and your homepage feed. See All Transportation
The Verge
13 hours ago
- The Verge
Hertz is selling its used cars on Amazon
Hertz has announced that it will start selling used cars from its rental business on Amazon Autos. The company's pre-owned vehicles are now available in Dallas, Houston, Los Angeles, and Seattle, according to a new page on Hertz's website, with 'more locations coming soon.' The Verge was unable to find any live Hertz vehicle listings at the time of writing. CNBC reports that customers living within 75 miles of the four launch cities can start browsing on Amazon Autos 'as soon as Wednesday' and that Hertz is planning to expand its operation to 45 locations across the US, bringing availability more in line with the wider list of Amazon Autos locations. 'Now you can conveniently shop our maintained-from-day-one vehicles on the online marketplace of - well - just about everything else,' Hertz says on its website. 'Just shop at Amazon Autos and pick up at your local Hertz Car Sales location within 3 days.' Amazon launched its Autos business in December last year, initially limited to selling new and 'certified pre-owned' Hyundai vehicles via a partnership with the Korean automaker's dealers in several states. Previously, customers could browse car showrooms and compare prices on Amazon but not actually buy a car. That changed last year when several Hyundai dealers started to list models for sale on the site. Hertz is the first rental fleet partnership for Amazon Autos, and will offer used vehicles from a wider variety of brands, including Ford, Toyota, Chevrolet, and Nissan. Posts from this author will be added to your daily email digest and your homepage feed. See All by Jess Weatherbed Posts from this topic will be added to your daily email digest and your homepage feed. See All Amazon Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Tech Posts from this topic will be added to your daily email digest and your homepage feed. See All Transportation
